Experiences with HCQ shortages among Canadian rheumatologists according to province of practice (n=134)
| Province* | British Columbia | Alberta | Saskatchewan | Manitoba | Ontario | Quebec | New Brunswick | Nova Scotia | Newfoundland and Labrador |
| Respondents (% total) | 14 (10) | 22 (16) | 3 (2) | 8 (6) | 48 (36) | 31 (23) | 3 (2) | 3 (2) | 2 (1) |
| COVID-19 cases per 100 000 population† | 36 | 84 | 28 | 19 | 88 | 256 | 15 | 85 | 49 |
| Concerned about HCQ shortage, n (%) | |||||||||
| Yes | 11 (79) | 16 (72) | 0 (0) | 5 (63) | 40 (83) | 27 (87) | 2 (67) | 0 (0) | 1 (50) |
| No | 0 (0) | 4 (18) | 0 (0) | 1 (13) | 4 (8) | 2 (6) | 1 (33) | 1 (33) | 0 (0) |
| Unsure | 3 (21) | 2 (9) | 3 (100) | 2 (25) | 4 (8) | 2 (6) | 0 (0) | 2 (67) | 1 (50) |
| Contacted by pharmacies or patients for HCQ access issues, n (%) | |||||||||
| Yes | 9 (64) | 9 (41) | 0 (0) | 2 (25) | 29 (60) | 29 (94) | 1 (33) | 1 (33) | 1 (50) |
| No | 5 (36) | 13 (59) | 3 (100) | 6 (75) | 19 (40) | 2 (6) | 2 (67) | 2 (67) | 1 (50) |
| Number of patients per physician affected by HCQ access issues, median (IQR)‡ | 5 (4–10) | 5 (3–13) | n/a | 3 (3–4) | 3 (2–6) | 50 (25–100) | 3§ | 1§ | 1§ |
| Number of patients per physician affected by HCQ access issues, mean (SD) ‡ | 6.9 (5.7) | 8.0 (8.3) | n/a | 3.0 (1.4) | 4.5 (3.8) | 74.9 (73.7) | 3§ | 1§ | 1 |
*No respondents from Prince Edward Island, Yukon, Northwest Territories or Nunavut.
†Estimates based on: Coronavirus Disease 2019 (COVID-19) Daily Epidemiology Update. Health Canada. https://www.canada.ca/content/dam/phac-aspc/documents/services/diseases/2019-novel-coronavirus-infection/surv-covid19-epi-update-eng.pdf; Statistics Canada. Table 17-10-0009-01, Population estimates, quarterly. DOI: https://doi.org/10.25318/1710000901-eng. Both accessed 23 April 2020.
‡Includes only respondents providing a numerical estimate of patients affected (n=71).
§n=1 respondent; median (IQR) and mean (SD) not calculated.
HCQ, hydroxychloroquine.